Home  /  Resource Library  /  CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

ASH 2020: Interim results of a phase investigating dual targeting CAR T-cell therapy for treatment of relapsed diffuse large b-cell lymphoma.